Clinical Trials · NCT00229658

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Name: An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/APramlintide

Phase: N/A
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 1,297
Start date: Sep 2005
Locations: 107 sites, United States
Primary endpoint: Incidence of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period

View Pramlintide compound reference